Market Trends Geron updates on Q4 revenue from U.S. sales of RYTELO (GERN:NASDAQ)By admin8996erT0allJanuary 13, 2025 Biopharmaceutical company Geron (NASDAQ:GERN) expects Q4 net revenue from the U.S. sales of the Telomerase Inhibitor RYTELO to be ~$45M…
